How does Mounjaro compare to Wegovy in clinical trials?
In a major head-to-head clinical trial with 750 adults with obesity, Mounjaro (tirzepatide) led to an average 20% body weight loss over 72 weeks, compared to 14% with Wegovy (semaglutide). Mounjaro also showed greater reductions in waist size and higher rates of achieving big weight loss goals, such as 25% body weight reduction in 32% of users versus 16% on Wegovy. Both drugs had similar side effects, mainly mild stomach issues.
Key points:
- Mounjaro users lost 20% of body weight on average, beating Wegovy's 14% in a direct 72-week trial.
- More people on Mounjaro hit top weight loss targets, like 25% reduction.
- Mounjaro cut waist size more, by 18cm versus 13cm for Wegovy.
- Women lost more weight than men on both drugs.
This text has been fact-checked for accuracy by Alessandro Grenci, Superintendent Pharmacist at medino.